The Foundation is pleased to announce that eleven research projects have been selected to share over $1.4M in research grants for its 2015-2016 research program. All applications received were evaluated by the Scientific Committee. The Foundation would like to thank all candidates who submitted a proposal.Read More
On June 23, a meeting was held in Montreal between a pharmaceutical company and the ARSACS research team with respect to the outcome of the preclinical trial phase II currently underway on the ARSACS mice at the Douglas Institute. The complete results should be known in November 2015. See Summary.
The meeting of the team of researchers “ARSACS – CIHR” held on June 3 provided an opportunity to share the most recent research results from each lab. See ARSACS meeting.
In February 2015,the Foundation funded a study conducted by Olivier Audet to determine the impact of a regular training program on ARSACS patients. The study shows a significant improvement for 11 of the 13 evaluations of physical fitness and the functional ability. See report(French version only) Mémoire.
The preparation required for a preclinical trial with a therapeutic molecule coming from the United States will begin soon. This test will be done on ARSACS mice in Montreal laboratories. This will be the 2nd preclinical trial funded by the Foundation. The results of the first trial are still to come.
Dr. Alanna Watt, member of the ARSACS research team, will be presenting the new ARSACS findings as a poster at the Neuroscience 2015 meeting. The annual meeting of the Society of Neuroscience will be held in October 2015 in Chicago. See New findings abstract.
The Ataxia Charlevoix-Saguenay Foundation was founded in 2006 to finance scientific research on Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS).Learn more
Again this year, with Mr. Jacques Bougie as the honorary president, the Dîner des Producteurs had a great success raising over $700,000 for the ARSACS reseach.Learn more
ARSACS is a debilating hereditary and progressive childhood neurological disorder.Learn more